Avadel Pharmaceuticals PLC at Needham Healthcare Conference Transcript
Good afternoon, everyone. Welcome to the session on Avadel. I'm Ami Fadia; I cover neuroscience and targeted oncology here at Needham. And it's my pleasure to be hosting Greg Divis, who is the CEO of the company. Greg, thank you for joining us today and taking the time.
Thanks, Ami. Appreciate the opportunity as always to spend some time with you. Thank you.
Questions & Answers
Perfect. So let's dive straight into the topic that's top of mind for everybody, which is what's going on with FT218 and when might we hear of an update. So in your last conference call and also some other conferences that you've been at in March, you talked about some interactions with the FDA that you've been having. Can you provide us with an update on where those interactions have -- what direction they've taken? Sounds like last time, you were waiting to hear back some feedback from the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
